Searched for
MARKETING MIRABEGRON
Zydus Lifesciences shares soar 7% to fresh record high after Q4 results. Should you buy, sell or hold?Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the J...- Zydus Lifesciences to pursue acquisitions in specialty, rare diseasesZydus Lifesciences is set to acquire US firm Assertio Holdings for $166.40 million. This move aims to build a strong specialty oncology bus...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Zydus settles US Mirabegron patent dispute with Astellas for $120 millionZydus Lifesciences and its US subsidiary have settled patent litigation with Astellas Pharma over Astellas' Myrbetriq. Zydus will pay Astel...
- Lupin clears Mirabegron patent dispute with Astellas in $90 million deal, secures US sales continuityDrugmaker Lupin has settled a patent infringement dispute with Astellas Pharma over its Mirabegron product for $90 million. The agreement i...
- Can domestic formulations shield Indian pharma from US pricing pressure in Q3?Indian drugmakers anticipate a mixed third quarter. Domestic sales and new specialty drugs will drive growth. US generics will see new prod...
- Lupin shares gain 3%, up for second straight session. Here’s whyLupin shares saw an uptick after Jefferies raised its target price and reiterated a “Buy” rating post-strong Q2 results. The US business hi...
- Buy, Sell or Hold: Nuvama raises target price on Cummins India; recommends buy on Lupin post Q2 resultsBrokerages maintained a bullish stance on Cummins India, Lupin, and Amara Raja Energy & Mobility, citing strong earnings, margin expansion,...
- Stocks to buy today: Wipro gets downgraded post Q4 results; Lupin could see over 20% upsideBrokerages are showing caution on specific stocks due to factors impacting earnings visibility. Nuvama downgraded Wipro to "Hold," citing w...
- Zydus Lifesciences Q1 results: Net profit jumps 31% to Rs 1420 croreThe earnings before interest, tax, depreciation and ammortisation (EBITDA) increased 38.4% YoY to Rs 2084 crore. On QoQ, EBITDA increased 2...
- Time to buy pharma? 3 stocks Forum Parekh is betting onZydus Life's US business is going to report a good set of numbers. Also, in India, wellness products are doing good, Overall Zydus Life wil...
- Zydus Lifesciences launches generic drug for overactive bladder in US marketZydus is among the first suppliers to launch the generic version of Mirabegron extended-release tablets (USP 25 mg) in the US market. The c...
- Just coming to our own in India; confident of growing our US business in next fiscal year: Lupin managementLupin's margin guidance remains around 19.5-20.5%. The company attributes its success to the pivot to complex products, cost-led initiative...
- Getting back into shape? 6 Indian pharma stocks with upside potential of up to 41%The year 2024, started with a correction in nifty, but one set of stocks which were able to outperform were pharma stocks. While it might a...
- Nifty healthcare index stocks analysts suggest buying have potential upside of more than 19%Except for a pocket in which demand for covid drugs led to sharp surge in pharma stocks, the pharma sector had been under pressure for a lo...
- Zydus Lifesciences rises 4% on getting approval from USFDA for Mirabegron Tablets“Zydus was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Mirabegron Extend...
- Lupin rallies 4% after multiple approvals from USFDAIn a regulatory filing, the company said it has received approval from the USFDA for mirabegron extended-release tablets.
- Stocks in the news: Here Moto, Indian Oil, Lupin, PNB and Adani Group stocksHero MotoCorp, the two-wheeler manufacturer, said it will invest $60 million in US-based Zero motorcycles to jointly develop electric motor...
- Stocks in the news: Cox & Kings, Sadbhav Infra, Lupin, Tata Steel & Sun PharmaNMDC has terminated a Rs 1,400-cr contract with BHEL for building the raw material handling system.
- Zydus Cadila gets tentative USFDA nod for overactive bladder treatment drugThe product will be manufactured at the group's manufacturing facility at SEZ in Ahmedabad.
Load More
